TSG Advice Partners LLC Purchases 3,310 Shares of Eli Lilly and Company $LLY

Key Points

• TSG Advice Partners LLC opened a position in Eli Lilly, buying 3,310 shares worth about $3.97 million. The stock represents roughly 0.5% of the fund’s portfolio.
• Eli Lilly reported quarterly EPS of $7.48, beating estimates of $5.71, and revenue of $24.4 billion, up 38.6% year over year. The article also says the company raised its 2026 revenue outlook to $91 billion–$92 billion.
• Institutional investors own 82.53% of Lilly shares. Recent analyst ratings were broadly positive, with a consensus “Moderate Buy” rating and an average price target of $1,404.14.

TSG Advice Partners LLC acquired a new stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) during the third quarter, according to its most recent filing with the SEC. The fund acquired 3,310 shares of the company's stock, valued at approximately $3,970,000. Eli Lilly and Company accounts for approximately 0.5% of TSG Advice Partners LLC's investment portfolio, making the stock its 27th biggest holding.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Capital CS Group LLC purchased a new position in shares of Eli Lilly and Company during the 3rd quarter valued at $510,000. Independence Wealth Advisors LLC grew its position in Eli Lilly and Company by 14.9% during the third quarter. Independence Wealth Advisors LLC now owns 309 shares of the company's stock worth $358,000 after buying an additional 40 shares in the last quarter. One Way Holdings LLC grew its position in Eli Lilly and Company by 7.9% during the third quarter. One Way Holdings LLC now owns 17,852 shares of the company's stock worth $20,656,000 after buying an additional 1,301 shares in the last quarter. Vigilare Wealth Management increased its stake in Eli Lilly and Company by 32.9% in the 3rd quarter. Vigilare Wealth Management now owns 1,819 shares of the company's stock worth $2,106,000 after acquiring an additional 450 shares during the last quarter. Finally, Welch Group LLC increased its stake in Eli Lilly and Company by 6.9% in the 3rd quarter. Welch Group LLC now owns 16,100 shares of the company's stock worth $18,629,000 after acquiring an additional 1,036 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $1,408.68 on Wednesday. The stock has a market cap of $1.33 trillion, a PE ratio of 45.72, a PEG ratio of 1.77 and a beta of 0.40. The company's fifty day moving average is $1,204.03 and its 200 day moving average is $1,095.92. Eli Lilly and Company has a 52 week low of $850.51 and a 52 week high of $1,449.68. The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The business had revenue of $24.40 billion during the quarter, compared to analyst estimates of $22.58 billion. During the same period in the prior year, the business posted $7.02 earnings per share. The company's revenue was up 38.6% on a year-over-year basis. Research analysts anticipate that Eli Lilly and Company will post 35.61 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company's payout ratio is 22.46%.

Insider Activity

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the transaction, the executive vice president directly owned 54,147 shares of the company's stock, valued at $63,628,139.70. The trade was a 10.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the business's stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the completion of the sale, the executive vice president owned 4,137 shares of the company's stock, valued at $5,802,225.24. The trade was a 54.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 18,500 shares of company stock valued at $22,970,770. Insiders own 0.14% of the company's stock.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s third-quarter revenue of $24.4 billion and EPS of $7.48 topped estimates, while revenue rose 38.6% year over year. The company raised its 2026 revenue outlook to $91 billion–$92 billion, reinforcing the demand-driven growth case. Raised Guidance Altering The Investment Case For Eli Lilly Stock?
• Positive Sentiment: Mounjaro and Zepbound remain key growth engines. Retatrutide also showed encouraging Phase 3 results versus Ozempic 2 mg in a diabetes trial, strengthening Lilly’s competitive position and future pipeline prospects. Eli Lilly Just Gained 22% in a Month
• Positive Sentiment: Cantor Fitzgerald raised its price target to $1,600 from $1,440 and maintained an “overweight” rating, reflecting optimism about the company’s outlook.
• Neutral Sentiment: EVP Anat Hakim sold 5,000 shares under a pre-arranged Rule 10b5-1 plan. The sale reduced her direct holdings by 54.72%, though planned insider transactions may carry less information than discretionary sales. SEC Form 4 filing
• Negative Sentiment: Some commentary warns that expectations may be ahead of sustainable growth: revenue growth could moderate, realized drug prices are reportedly falling, and some recent revenue contributions may not recur. A high valuation makes the shares more sensitive to any slowdown. Eli Lilly: Priced For Acceleration, Reporting Deceleration
• Negative Sentiment: Pipeline setbacks and dropped drug candidates outside the GLP-1 franchise raise questions about whether Lilly can broaden growth beyond its current blockbuster products. Lilly’s R&D whirlwind

Analysts Set New Price Targets

LLY has been the topic of several recent analyst reports. Citigroup raised their price target on Eli Lilly and Company from $1,600.00 to $1,650.00 and gave the company a "buy" rating in a report on Friday, October 30th. Wall Street Zen raised Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Saturday. Royal Bank Of Canada upped their price objective on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock an "outperform" rating in a research report on Friday, October 30th. Cantor Fitzgerald upped their price objective on shares of Eli Lilly and Company from $1,440.00 to $1,600.00 and gave the stock an "overweight" rating in a research report on Monday. Finally, Sanford C. Bernstein reaffirmed an "outperform" rating and issued a $1,450.00 target price on shares of Eli Lilly and Company in a research note on Monday, October 26th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and an average price target of $1,404.14.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.